O-RADS for Adnexal Lesions: Current Validation, Challenges, and Future Directions

O-RADS MRI validation studies show high specificity (90–95%) for adnexal lesion characterization. The 2022 O-RADS US update refined descriptors to improve specificity while maintaining high sensitivity and reproducibility.

• Design: Narrative review summarizing validation and updates for the ACR O-RADS ultrasound and MRI risk-stratification systems.
• Key secondary finding: O-RADS US demonstrates high sensitivity for malignancy detection and strong interobserver agreement across validation studies (exact figures not reported in source).
• Limitation: Not a systematic review or meta-analysis; quantitative performance metrics are drawn from cited individual studies summarized narratively.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.